je.st
news
Tag: merck
Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (MK-5172/MK-8742) at the 65th American Association for the Study of Liver Diseases Annual Meeting
2014-10-08 17:13:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Interim results of C-SWIFT, a Phase 2 study evaluating ultra-short treatment durations of grazoprevir/elbasvir (MK-5172/MK-8742) plus sofosbuvir, to be presented Results from the C-WORTHy study, a Phase 2 clinical trial evaluating grazoprevir/elbasvir (MK-5172/MK-8742) across multiple patient populations, including difficult-to-cure, to be presented WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data from clinical studies of the companys investigational, oral, once-daily, fixed-dose combination chronic hepatitis C treatment grazoprevir/elbasvir (MK-5172/MK-8742) are scheduled to be presented at the 65th American Association for the Study of Liver Diseases (AASLD) Annual Meeting, also known as The Liver Meeting. The meeting is scheduled to take place at the John B. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: of
data
present
american
Merck Prices EUR 2.5 Billion Debt Offering
2014-10-06 18:28:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (the Company) (NYSE:MRK), known as MSD outside of the United States and Canada, priced today EUR 2.5 billion public offering of three series of Euro-denominated senior unsecured notes (collectively, the New Notes). Based on Oct. 3, 2014, closing exchange rates the EUR 2.5 billion equates to approximately $3.1 billion. The notes include: Language: English Contact: Merck & Co., Inc.Media:Steven Cragle, 908-423-3461Lainie Keller, 908-236-5036Investor:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: eur
prices
offering
debt
Merck Announces Proposed Public Debt Offering
2014-10-06 09:24:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (the Company) (NYSE:MRK), known as MSD outside the United States and Canada, announced today the commencement of a public offering of three series of Euro denominated senior unsecured notes due 2021, 2026 and 2034 (collectively, the New Notes). The exact terms and timing of the offering will depend upon market conditions and other factors. Language: English Contact: Merck & Co., Inc.Media:Steve Cragle, 908-423-3461Lainie Keller, 908-236-5036orInvestor:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: public
proposed
offering
debt
Merck Announces Tender Offers for Eight Series of Notes
2014-10-06 09:18:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (Merck) (NYSE:MRK), known as MSD outside the United States and Canada, announced today the commencement of offers to purchase (collectively, the Offers) any and all of the outstanding notes listed below (collectively, the Notes). The Offers are being made upon, and are subject to, the terms and conditions set forth in the Offer to Purchase, dated Oct. 6, 2014 (Offer to Purchase). Language: English Contact: Merck & Co., Inc.MediaSteve Cragle, 908-423-3461Lainie Keller, 908-236-5036orInvestor:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck Congratulates Ecuador as Second Country to Receive PAHO/WHO Verification of Elimination of River Blindness
2014-10-03 15:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, applauds the government of Ecuador on being the second country in the world to receive World Health Organization (WHO) verification of the elimination of river blindness (onchocerciasis) using MECTIZAN (ivermectin). Language: English Contact: MerckJennifer Woodruff, 267-305-3550 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: country
receive
river
ecuador
Sites : [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] next »